Modulation of activity of neurotrophins

Patent metadata

Field	Value
Publication number	US-9605073-B2
Application number	US-201514621589-A
Country	US
Kind code	B2
Filing date	Feb 13, 2015
Priority date	Dec 20, 2002
Publication date	Mar 28, 2017
Grant date	Mar 28, 2017

Abstract

The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.

First claim

The invention claimed is:

1. A method of treating a neurological disease or disorder in a mammal by promoting survival and/or growth of neurons, said method comprising administering to said mammal a therapeutically effective amount of an antibody that binds an extracellular part of a Sortilin receptor comprising amino acids 612-740 of SEQ ID NO: 1, and thereby inhibits binding of a pro-neurotrophin to said receptor.

2. The method of claim 1 , wherein the disease or disorder is selected from the group consisting of: inflammatory pain, Charcot-Marie-Tooth disease, Refsum's disease, Abetalipoproteinemia, Tangier disease, Krabbe's disease, Metachromatic leuko-dystrophy, Fabry's disease, and Dejerine-Sottas syndrome, depression, mania or Down's syndrome.

3. The method of claim 1 , wherein said pro-neurotrophin is selected from the group consisting of pro-NGF, pro-BDNF, pro-NT-3 and pro-NT-4/5.

4. The method of claim 1 , wherein said antibody is administered in a therapeutically effective amount of from about 1 μg/kg to about 100 mg/kg per day.

5. The method of claim 1 , wherein the mammal is a human being.

Assignees

• H Lundbeck
• H Lundbeck As

Inventors

• Nykjaer Anders
• Petersen Claus Munck

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P25/02

  for peripheral neuropathies · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title